key: cord-0266898-f3wq7j5u
authors: Kared, H.; Wolf, A.-S. F. M.; Alirezaylavasani, A.; Ravussin, A.; Solum, G.; Tran, T. T.; Lund-Johansen, F.; Vaage, J. T.; Nissen-Meyer, L. S.; Nygaard, U. C.; Hungnes, O.; Robertson, A. H.; Meyer Naess, L.; Trogstad, L.; Magnus, P.; Munthe, L. A.; Mjaaland, S.
title: Immunity in Omicron SARS-CoV-2 breakthrough COVID-19 in vaccinated adults
date: 2022-01-13
journal: nan
DOI: 10.1101/2022.01.13.22269213
sha: 213b45912d7dcfc30276d303b2c19ff215682298
doc_id: 266898
cord_uid: f3wq7j5u

The new SARS-CoV-2 variant of concern (VOC) Omicron has more than 30 mutations in the receptor binding domain (RBD) of the Spike protein enabling viral escape from antibodies in vaccinated individuals and increased transmissibility. It is unclear how vaccine immunity protects against Omicron infection. Here we show that vaccinated participants at a superspreader event had robust recall response of humoral and pre-existing cellular immunity induced by the vaccines, and an emergent de novo T cell response to non-Spike antigens. We compared cases from a Christmas party where 81 of 110 (74%) developed Omicron breakthrough COVID-19, with Delta breakthrough cases and vaccinated non-infected controls. Omicron cases had significantly increased activated SARS-CoV-2 wild type Spike-specific (vaccine) cytotoxic T cells, activated follicular helper (TFH) cells, functional T cell responses, boosted humoral responses, activated anti-Spike plasmablasts and anti-RBD memory B cells compared to controls. Omicron cases had significantly increased de novo memory T cell responses to non-Spike viral antigens compared to Delta breakthrough cases demonstrating development of broad immunity. The rapid release of Spike and RBD-specific IgG+ B cell plasmablasts and memory B cells into circulation suggested affinity maturation of antibodies and that concerted T and B cell immunity may provide durable broad immunity.

but reports suggest increased transmission in South Africa 2 , and a 40-fold reduced effect of 44 IgG neutralizing antibodies in Pfizer BNT162b2-vaccinated patients as analyzed in Omicron 45 VOC neutralization assays 9 . The Omicron VOC has since been found in over 89 countries as 46 of mid-January 2021. 47 In contrast to the serological epitopes, bioinformatic analyses suggest that most 48 immunodominant T cell epitopes are conserved 10 . We aimed to test if cases had fully functional 49 vaccine generated T cell responses and to provide in-depth analyses of the immune responses 50 in Omicron breakthrough COVID-19. 51 We found that the Omicron and Delta breakthrough COVID-19 cases were all mild and did not 52 require hospitalization. 6-13 days after symptoms debut, no major changes were found in 53 lymphocyte, monocyte or granulocyte counts (data not shown). The cases had near normalized To determine the activation of vaccine T cell immunity, we detected CD8 + T cells specific for 61 Spike peptides with MHC-class I restricted multimers (See Methods). We also performed 62 deep immune-phenotyping to detect markers that correlate with protective immune responses 63 in mild COVID-19, and quantified cells (see below). High dimensionality analyses of 64 Omicron cases revealed that nearly all Spike-specific CD8 + T cells were activated expressing As a corollary to the expanded and activated state of vaccine-specific CD8 + T cells, we found 92 that the Omicron breakthrough cases had significantly increased frequency of in vitro CD8 + T 93 cell responses to Spike peptides, including significantly increased CD137 + cells that secreted 94 IL-2, IFN-γ, and TNF (Fig 1e) . Functional responses from SARS-CoV-2 specific CD8 + T 95 cells were barely detectable in vaccinated healthy donors (3-4 months post-vaccine) but were 96 still strong in convalescent patients (3-6 months post recovery). 97 We next analyzed functional CD8 + T cell responses to other (non-Spike) antigens of the 98 SARS-CoV-2 virus. Omicron and Delta breakthrough COVID-19 cases had Membrane-, 99 Nucleoprotein-and ORF-specific T cells but lower responses than observed in recovered 100 convalescent patients ( Figure 1f ). Hence, strong vaccine-specific CD8 + T cell immunity was 101 accompanied by emergent immunity to SARS-CoV-2 epitopes that included a multitude of 102 epitopes. CD8 + T cells from Delta-infected patients also presented increased cytotoxic Among the other T cell subsets, we observed a peripheral decrease of TCRγ/δ + T cells, and 107 no significant modulation of MAIT cells or CD4/CD8 ratio (data not shown). In the T helper 108 (Th) subsets, we did not observe any general upregulation of markers associated with T cell 109 differentiation, activation, exhaustion or senescence. However, we next evaluated whether T perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.13.22269213 doi: medRxiv preprint (not expressing IgM or IgD) were significantly more likely to express IgG in Omicron than in 142 Delta cases. This applied both for anti-RBD and anti-Spike (non-RBD), with p=0.0062 and 143 p=0.0215 respectively, (Extended Data Figure 4 ). As expected, the concentration of anti-144 RBD IgG correlated significantly with the frequency of Spike-specific B cells (p=0.0003), 145 increased significantly with time post-infection (p=0.0004), and the age of the participants 146 was negatively associated with the humoral response in our small cohort (p=0.0189), 147 Extended Data Figure 4 . 148 The most striking B cell response in Omicron COVID-19 cases was significantly increased 149 Spike-specific plasma blasts (CD38 hi CD27 hi CD21 low CD24 neg CD71 hi IRF4 + BLIMP-1 + ) where We here describe robust T cell activation towards SARS-CoV-2 vaccine peptide antigens in 156 breakthrough infections of cases with the SARS-CoV-2 Omicron VOC. The T cell phenotype 157 corresponded to successful protective T cell immunity in COVID-19 convalescents including 158 activation markers and lack of exhaustion markers. A more potent activation was seen in 159 Omicron than in the Delta breakthrough cases where T cell phenotypes were consolidated (in 160 terms of effector markers) rather than activated. As a corollary, in vitro challenge with 161 SARS-CoV-2 Spike peptides demonstrated a significantly increased T cell responsiveness for 162 both CD4 + T helper cells and CD8 + T cells. We also found a robust emergent T cell immunity 163 towards other SARS-CoV-2 non-vaccine peptides suggesting development of broad T cell 164 responses. This was accompanied by a significantly boosted IgG anti-RBD response and a surge of IgG + RBD and Spike specific B cells that were plasma cell precursors or activated 166 memory B cells. 167 In the current study, as many as 74% of the participants developed Omicron COVID despite 168 being fully vaccinated. Preliminary analyses 9 suggest that the increased transmission and 169 breakthrough infections relate to escape of antibody neutralization as sera from Pfizer 170 BNT162b2-vaccinated individuals had dramatically reduced viral neutralization. In addition, 171 neutralizing antibodies (NAbs) peak and decay with time after vaccination. 18 Most infected 172 individuals at the Christmas party were young to mid-aged adults that had been vaccinated 3-173 6 months before the party, suggesting some decay of NAb titers.

If Omicron escapes protective antibodies, exposed individuals will rely on the collaboration 175 between vaccine expanded T cell and B cell responses to counteract the Omicron infection. Importantly, in contrast to decaying antibody titres, SARS CoV-1 T cell memory was long-180 lasting and was found after 17 years. 19 The importance of T cells has been underlined in 181 previous reports as T cells are necessary for rapid and efficient resolution of COVID-19, for 182 protection against severe COVID-19 in settings of low antibody levels, and for rapid viral 183 control in the absence of antibodies -aborting infection in healthy individuals.

The current results demonstrate a potent activation of vaccine-specific T cell responses in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.13.22269213 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.13.22269213 doi: medRxiv preprint Methods 1 Cases and controls 2 We included four main cohorts: 1) participants from the Christmas party with Omicron VOC 3 COVID-19 (n=13, mild disease) as described 1, 2) donors with breakthrough Delta VOC 4 COVID-19 (n=13, mild disease) from the Norwegian Institute of Public Health (NIPH) Young 5 Adult cohort (see Table 1 and Extended Data Fig. 1 for overview of cases) , 3) control fully This sample was transferred to the Omicron cases for a total of n=13. Previous COVID-19 n (%) 0 1 (7.7) 0 * one of the Young Adult cohort was found to be infected with the Omicron variant and was 24 subsequently included with the other Omicron cases. Table S2 . i.e. stimulated with M+N+O, Figure 1f perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.13.22269213 doi: medRxiv preprint

O O O D O O D O O D D O D D D D D D H H D D O H O O H D H H H H H IgD IgM CD21 CD24 CD71 BLIMP1 CD38 IRF4 CD27 IgG Patient Patient Delta HD Omicron

Antigen-specific CD8 T cells were detected by peptide: HLA multimers (see Supplementary   103   Table S2 for overview). Spike Specific CTL were detected using PE-conjugated Dextramers perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.13.22269213 doi: medRxiv preprint Antigen-specific multimer CD8 T cells were identified by fine manual gating.The designation 126 of bona fide antigen-specific T cells was further dependent on (a) the detection cut-off 127 threshold (≥ 5 events to be detected), (b) the background noise (frequencies of specific CD8 + 128 T cells must be greater than frequencies from the corresponding CD4 + T cell population) as 129 unbiased objective criteria for antigen-specificity assessment. Spike and non-Spike perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 13, 2022. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.13.22269213 doi: medRxiv preprint acquired on FACSymphony. All Antibodies were purchased from BD biosciences except 191 towards Blimp-1 and IRF4 (Thermofischer) and IgM, CD71 and HLA-DR (Biolegend).

The following enzyme-linked immunosorbent assay (ELISA) kits were used according to perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in shows positive linear correlation, and red color shows negative linear correlation. All 218 statistical analyses were performed using GraphPad Prism and R. Statistical significance was 219 set at a threshold of *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 13, 2022. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 13, 2022. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 13, 2022. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.13.22269213 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 13, 2022. ; https://doi.org/10.1101/2022.01.13.22269213 doi: medRxiv preprint perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted January 13, 2022. 

Spike_A0201_HD9_009.fcs Spike_A0101_A1101_HD004_027.fcs Spike_B0702_HD9_019.fcs Spike_A2402_HD5_013.fcs Spike_A0101_A1101_OMICRON_12_004.fcs Spike_A0201_Delta_01_053.fcs Spike_A0201_Delta_07_055.fcs Spike_A2402_Delta_08_072.fcs Spike_A2402_Delta_14_077.fcs Spike_A2402_Delta_07_071.fcs Spike_A2402_HD_11_078.fcs Spike_A0101_Delta_08_047.fcs Spike_A0101_Delta_06_046.fcs Spike_A0101_Delta_11_048.fcs Spike_B0702_OMICRON_10_017.fcs Spike_B0702_OMICRON_12_018.fcs Spike_A2402_HD_13_079.fcs Spike_A2402_HD_13_080.fcs Spike_A0101_HD12_052.fcs Spike_B0702_HD13_067.fcs Spike_A2402_Delta_13_076.fcs Spike_A2402_OMICRON_6_010.fcs Spike_A2402_HD9_015.fcs Spike_A2402_OMICRON_10_012.fcs Spike_A2402_Delta_12_075.fcs Spike_A2402_Delta_01_068.fcs Spike_A2402_Delta_04_069.fcs Spike_A2402_Delta_05_070.fcs

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway

Comprehensive analysis of T cell immunodominance and immunoprevalence 229 of SARS-CoV-2 epitopes in COVID-19 cases

SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 232 individuals

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T 234 cell recognition

SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance 236 and substantial CD8(+) T cell activation in COVID-19 patients

Abstract S05-01: Profound CD8 T-cell responses towards SARS-CoV

Identification and characterization of a SARS-CoV-2 specific CD8(+) T cell 242 response with immunodominant features

Unbiased Screens Show CD8<sup>+</sup> T Cells of COVID-19 Patients 245

Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild 248 COVID-19

SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse 250 Repertoire of Human T Cell Receptors

ORF_N_A0201_HD08_033.fcs ORF_N_A0201_HD04_032.fcs ORF_N_A0201_OMICRON_09_031.fcs ORF_N_A0201_OMICRON_4_005.fcs ORF_N_A0201_HD9_009.fcs ORF_N_A0201_OMICRON_05_030.fcs ORF_N_A0201_HD5_007.fcs ORF_N_A0201_HD6_008.fcs ORF_N_B0702_OMICRON_04_016.fcs ORF_N_B0702_OMICRON_05_039.fcs ORF_N_B0702_OMICRON_01_037.fcs ORF_N_B0702_OMICRON_07_040.fcs ORF_N_B0702_OMICRON_11_041.fcs ORF_N_B0702_Delta_06_063.fcs ORF_N_B0702_Delta_03_062.fcs ORF_N_A0101_A1101_OMICRON_12_004.fcs ORF_N_A0101_Delta_13_049.fcs ORF_N_A0101_HD10_051.fcs ORF_N_B0702_OMICRON_10_017.fcs ORF_N_B0702_OMICRON_12_018.fcs ORF_N_A0101_HD12_052.fcs ORF_N_B0702_HD13_067.fcs ORF_N_A2402_HD_13_079.fcs ORF_N_A2402_HD_13_080.fcs ORF_N_A0101_Delta_05_045.fcs ORF_N_A0101_Delta_11_048.fcs ORF_N_A0101_Delta_14_050.fcs ORF_N_A0101_Delta_04_044.fcs ORF_N_A0101_Delta_06_046.fcs ORF_N_A0201_HD11_059.fcs ORF_N_A0101_A1101_OMICRON_04_001.fcs ORF_N_A0101_A1101_OMICRON_06_002.fcs ORF_N_A0101_A1101_OMICRON_9_025.fcs ORF_N_A0101_A1101_OMICRON_11_026.fcs ORF_N_A0101_A1101_OMICRON_1_023.fcs ORF_N_A0101_A1101_OMICRON_7_024.fcs ORF_N_B0702_OMICRON_03_038.fcs ORF_N_A0101_A1101_OMICRON_02.fcs ORF_N_A0101_A1101_OMICRON_10_003.fcs